Join the Urticaria group to help and get support from people like you.
Urticaria News
Related terms: Urticarial disorders
Urticaria Reported in Trial of Investigational HIV mRNA Vaccines
MONDAY, May 5, 2025 – Urticaria is seen in association with experimental HIV-1 mRNA vaccination, according to a study published online April 29 in the Annals of Internal Medicine. Sharon A. Riddler,...
FDA Approves Dupixent for Chronic Spontaneous Urticaria
WEDNESDAY, April 23, 2025 – The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adults and adolescents with chronic spontaneous urticaria. The approval is...
Dupixent (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)
TARRYTOWN, N.Y. and PARIS, April 18, 2025 (GLOBE NEWSWIRE) – Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved...
Remibrutinib Beneficial for Urticaria After H1-Antihistamine Treatment
TUESDAY, March 11, 2025 – For patients with symptomatic chronic spontaneous urticaria after treatment with second-generation H1-antihistamines, administration of the oral, highly selective Bruton's...
FDA Approves Omlyclo (omalizumab-igec), an Interchangeable Biosimilar to Xolair
JERSEY CITY, N.J., March 9, 2025 /PRNewswire/ – Celltrion today announced the U.S. Food and Drug Administration (FDA) approved Omlyclo® (omalizumab-igec) as the first and only biosimilar designated a...
FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications
South San Francisco, CA – April 12, 2021 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved the...
FDA Approves Quzyttir (cetirizine) Injection for the Treatment of Acute Urticaria
October 11, 2019 - The U.S. Food and Drug Administration (FDA) has approved Quzyttir (cetirizine hydrochloride) injection for the treatment of acute urticaria in adults and children 6 months of age...
FDA Approves Xolair (omalizumab) for Chronic Idiopathic Urticaria
South San Francisco, Calif. – March 21, 2014 – Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) approved Xolair (omalizumab) for the...
Further information
Related condition support groups
Related drug support groups
Benadryl, Zyrtec, Claritin, diphenhydramine, Allegra, loratadine, promethazine, Dupixent, famotidine, view more... cetirizine, Xolair, doxepin, Phenergan, fexofenadine, omalizumab, dupilumab, cyproheptadine